{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:09:18Z","timestamp":1788786558726,"version":"build-2803163510"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Obesity-related functional hypogonadism (FH) is a potentially reversible condition associated with sexual dysfunction, metabolic disorders, altered body composition, and impaired quality of life. Although several treatment strategies are available, their comparative benefits and safety remain uncertain. This systematic review and network meta-analysis aimed to characterize their outcome-specific effects and the confidence of the comparative evidence in adult men with obesity-related FH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to April 2026 for randomized controlled trials evaluating structured lifestyle therapy (SLT), testosterone replacement therapy (TRT), endogenous testosterone restoration (ETR) therapy, glucagon-like peptide-1 receptor agonist\u2013based therapy, or TRT plus SLT. Frequentist network meta-analyses were performed. Risk of bias was assessed using RoB 2, and confidence in the evidence was evaluated using CINeMA. Sensitivity and direct-evidence analyses were conducted to examine the robustness of the principal findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-three randomized controlled trials involving 1899 participants were included. Compared with usual care\/placebo, TRT plus SLT showed the largest estimated increase in total testosterone (MD 7.19, 95% CI, 1.18-13.21), followed by ETR therapy (MD 4.14, 95% CI, 0.74-7.54) and TRT (MD 2.53, 95% CI, 0.26-4.81). Testosterone replacement therapy plus SLT significantly improved International Index of Erectile Function scores (MD 1.29, 95% CI, 0.07-2.50). No intervention significantly reduced glycated hemoglobin compared with usual care\/placebo. Testosterone replacement therapy reduced waist circumference and increased lean mass but also increased hematocrit; ETR therapy and TRT plus SLT also increased lean mass. No significant differences in adverse events were detected. Sensitivity and direct-evidence analyses generally supported the direction of the principal findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Available treatments showed distinct outcome-specific effects, but no single strategy was consistently superior across all outcomes. Confidence in many comparisons was low or very low, and the included trials differed in participant characteristics, treatment protocols, and follow-up duration. These findings should inform individualized treatment decisions rather than a definitive treatment ranking, and require confirmation in longer-term head-to-head trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdag272","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:48:43Z","timestamp":1787226523000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment strategies for functional hypogonadism in obese men: a systematic review and network meta-analysis"],"prefix":"10.1093","volume":"23","author":[{"given":"Liangliang","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Health Management Center and Institute of Health Management, Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China , Chengdu 610031 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlei","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China , Chengdu 610072 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shize","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China , Chengdu 610072 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingxin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Health Management Center and Institute of Health Management, Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China , Chengdu 610031 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenrui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Shenzhen Hospital of Traditional Chinese Medicine, Futian District , Shenzhen 518000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Urology, Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China , Chengdu 610072 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"issue":"10","key":"2026090708273334700_ref1","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1038\/s41591-025-03978-z","article-title":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"2026090708273334700_ref2","doi-asserted-by":"publisher","first-page":"93689","DOI":"10.5493\/wjem.v14.i2.93689","article-title":"Management of male obesity-related secondary hypogonadism: a clinical update","volume":"14","author":"Shenoy","year":"2024","journal-title":"World J Exp Med"},{"issue":"9","key":"2026090708273334700_ref3","doi-asserted-by":"publisher","first-page":"e3125","DOI":"10.1210\/clinem\/dgaf137","article-title":"Approach to the patient: low testosterone concentrations in men with obesity","volume":"110","author":"Muir","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026090708273334700_ref4","doi-asserted-by":"publisher","first-page":"e76139","DOI":"10.7759\/cureus.76139","article-title":"Impact of weight loss on testosterone levels: a review of BMI and testosterone","volume":"16","author":"Okobi","year":"2024","journal-title":"Cureus"},{"issue":"5","key":"2026090708273334700_ref5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/andr.12770","article-title":"European academy of andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization: European society of endocrinology","volume":"8","author":"Corona","year":"2020","journal-title":"Andrology."},{"issue":"6","key":"2026090708273334700_ref6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4103\/aja.aja_44_18","article-title":"Secondary male hypogonadism: a prevalent but overlooked comorbidity of obesity","volume":"20","author":"Molina-Vega","year":"2018","journal-title":"Asian J Androl"},{"key":"2026090708273334700_ref7","doi-asserted-by":"publisher","first-page":"e948180","DOI":"10.12659\/MSM.948180","article-title":"Mechanisms of Leydig cell aging and obesity-related hypogonadism in men: a review","volume":"31","author":"Huang","year":"2025","journal-title":"Med Sci Monit"},{"issue":"4","key":"2026090708273334700_ref8","doi-asserted-by":"publisher","first-page":"15579883251343972","DOI":"10.1177\/15579883251343972","article-title":"Impact of symptoms of late-onset hypogonadism as a potential driver of presenteeism","volume":"19","author":"Shirakawa","year":"2025","journal-title":"Am J Mens Health"},{"issue":"2","key":"2026090708273334700_ref9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.17925\/EE.2019.15.2.83","article-title":"Male obesity-related secondary hypogonadism - pathophysiology, clinical implications and management","volume":"15","author":"Fernandez","year":"2019","journal-title":"Eur Endocrinol"},{"issue":"3","key":"2026090708273334700_ref10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1530\/EJE-12-0890","article-title":"Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European male ageing study","volume":"168","author":"Camacho","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2026090708273334700_ref11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"2026090708273334700_ref12","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1002\/cl2.1080","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"issue":"11","key":"2026090708273334700_ref13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026090708273334700_ref14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"issue":"4","key":"2026090708273334700_ref15","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"issue":"3","key":"2026090708273334700_ref16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/jrsm.1397","article-title":"A comparison of Bayesian and frequentist methods in random-effects network meta-analysis of binary data","volume":"11","author":"Seide","year":"2020","journal-title":"Res Synth Methods"},{"key":"2026090708273334700_ref17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12916-024-03322-1","article-title":"Low awareness of the transitivity assumption in complex networks of interventions: a systematic survey from 721 network meta-analyses","volume":"22","author":"Spineli","year":"2024","journal-title":"BMC Med"},{"key":"2026090708273334700_ref18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"2026090708273334700_ref19","doi-asserted-by":"publisher","first-page":"e814","DOI":"10.1210\/clinem\/dgae249","article-title":"Metabolic effects of testosterone added to intensive lifestyle intervention in older men with obesity and hypogonadism","volume":"110","author":"Gonzalez-Gil","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026090708273334700_ref20","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s41366-018-0105-2","article-title":"Effects of clomiphene citrate on male obesity-associated hypogonadism: a randomized, double-blind, placebo-controlled study","volume":"42","author":"Soares","year":"2018","journal-title":"Int J Obes"},{"issue":"10","key":"2026090708273334700_ref21","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1111\/j.1743-6109.2010.01931.x","article-title":"Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study","volume":"7","author":"Aversa","year":"2010","journal-title":"J Sex Med"},{"issue":"3","key":"2026090708273334700_ref22","doi-asserted-by":"publisher","first-page":"e1096","DOI":"10.1210\/clinem\/dgaa917","article-title":"Testosterone replacement therapy added to intensive lifestyle intervention in older men with obesity and hypogonadism","volume":"106","author":"Barnouin","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026090708273334700_ref23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2337\/dc15-1518","article-title":"Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes","volume":"39","author":"Dhindsa","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"2026090708273334700_ref24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/bju.13337","article-title":"Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement","volume":"117","author":"Kim","year":"2016","journal-title":"BJU Int"},{"issue":"1","key":"2026090708273334700_ref25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11357-011-9213-9","article-title":"Testosterone therapy increased muscle mass and lipid oxidation in aging men","volume":"34","author":"Frederiksen","year":"2012","journal-title":"Age (Dordr)"},{"key":"2026090708273334700_ref26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fendo.2020.00277","article-title":"Aromatase inhibitors plus weight loss improves the hormonal profile of obese hypogonadal men without causing major side effects","volume":"11","author":"Colleluori","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2026090708273334700_ref27","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.2337\/dc13-2845","article-title":"Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial","volume":"37","author":"Gianatti","year":"2014","journal-title":"Diabetes Care"},{"issue":"7","key":"2026090708273334700_ref28","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1111\/j.1743-6109.2010.01859.x","article-title":"Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome","volume":"7","author":"Giltay","year":"2010","journal-title":"J Sex Med"},{"issue":"3","key":"2026090708273334700_ref29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/13685538.2018.1468429","article-title":"The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes","volume":"21","author":"Groti","year":"2018","journal-title":"Aging Male"},{"issue":"3","key":"2026090708273334700_ref30","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/jsm.12404","article-title":"Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study","volume":"11","author":"Hackett","year":"2014","journal-title":"J Sex Med"},{"issue":"6","key":"2026090708273334700_ref31","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2164\/jandrol.108.007005","article-title":"Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone","volume":"30","author":"Heufelder","year":"2009","journal-title":"J Androl"},{"issue":"3","key":"2026090708273334700_ref32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EC-18-0514","article-title":"Effects of liraglutide on obesity-associated functional hypogonadism in men","volume":"8","author":"Jensterle","year":"2019","journal-title":"Endocr Connect"},{"issue":"4","key":"2026090708273334700_ref33","doi-asserted-by":"publisher","first-page":"828","DOI":"10.2337\/dc10-1233","article-title":"Testosterone replacement in hypogonadal men with type 2 diabetes and\/or metabolic syndrome (the TIMES2 study)","volume":"34","author":"Jones","year":"2011","journal-title":"Diabetes Care"},{"issue":"5","key":"2026090708273334700_ref34","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/j.1365-2265.2010.03845.x","article-title":"Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study","volume":"73","author":"Kalinchenko","year":"2010","journal-title":"Clin Endocrinol"},{"issue":"4","key":"2026090708273334700_ref35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/13685538.2018.1506918","article-title":"Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial","volume":"22","author":"Khripun","year":"2019","journal-title":"Aging Male"},{"issue":"10","key":"2026090708273334700_ref36","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/dom.12701","article-title":"Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy","volume":"18","author":"Magnussen","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2026090708273334700_ref37","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/dom.16042","article-title":"Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism","volume":"27","author":"Gregori\u010d","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026090708273334700_ref38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12916-016-0700-9","article-title":"Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial","volume":"14","author":"Ng Tang Fui","year":"2016","journal-title":"BMC Med"},{"issue":"3","key":"2026090708273334700_ref39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12603-016-0698-x","article-title":"Effect of lifestyle intervention on the hormonal profile of frail, obese older men","volume":"20","author":"Armamento-Villareal","year":"2016","journal-title":"J Nutr Health Aging"},{"issue":"5","key":"2026090708273334700_ref40","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1530\/EJE-13-0190","article-title":"Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia","volume":"169","author":"Loves","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026090708273334700_ref41","doi-asserted-by":"publisher","first-page":"e12815","DOI":"10.1111\/and.12815","article-title":"Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: a subanalysis of a prospective randomised controlled trial (EARTH study)","volume":"50","author":"Shigehara","year":"2016","journal-title":"Andrologia"},{"issue":"3","key":"2026090708273334700_ref42","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/ejendo\/lvad099","article-title":"Leflutrozole in male obesity-associated hypogonadotropic hypogonadism: Ph 2b double-blind randomised controlled trial","volume":"189","author":"Jones","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026090708273334700_ref43","doi-asserted-by":"publisher","first-page":"e13697","DOI":"10.1002\/jcsm.13697","article-title":"Testosterone modulation of muscle transcriptomic profile during lifestyle therapy in older men with obesity and hypogonadism","volume":"16","author":"Viola","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"2026090708273334700_ref44","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/sxmrev\/qeaf036","article-title":"Male hypogonadism: recommendations from the fifth international consultation on sexual medicine (ICSM 2024)","volume":"13","author":"Khera","year":"2025","journal-title":"Sex Med Rev"},{"issue":"4","key":"2026090708273334700_ref45","doi-asserted-by":"publisher","first-page":"295","DOI":"10.65092\/autfm.1762927","article-title":"Diagnosis and treatment of primary, secondary, and functional male hypogonadism: a narrative review","volume":"78","author":"Mutlu","year":"2025","journal-title":"Ankara \u00dcniversitesi T\u0131p Fak\u00fcltesi Mecmuas\u0131"},{"issue":"11","key":"2026090708273334700_ref46","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3390\/medicina59111902","article-title":"Clomiphene citrate in the Management of Infertility in oligospermic obese men with hypogonadism: retrospective pilot study","volume":"59","author":"Panner Selvam","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"2026090708273334700_ref47","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12894-025-02005-0","article-title":"Effect of GLP-1 agonists on testosterone levels: a systematic review and meta-analysis","volume":"25","author":"Orra","year":"2025","journal-title":"BMC Urol"},{"issue":"3","key":"2026090708273334700_ref48","doi-asserted-by":"publisher","first-page":"256","DOI":"10.5534\/wjmh.190061","article-title":"Treatment of functional hypogonadism besides pharmacological substitution","volume":"38","author":"Corona","year":"2020","journal-title":"World J Mens Health"},{"issue":"1","key":"2026090708273334700_ref49","doi-asserted-by":"publisher","first-page":"2601423","DOI":"10.1080\/13685538.2025.2601423","article-title":"The male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems","volume":"28","author":"Antoni\u010d","year":"2025","journal-title":"Aging Male."},{"key":"2026090708273334700_ref50","doi-asserted-by":"publisher","first-page":"1719749","DOI":"10.3389\/fendo.2025.1719749","article-title":"Testosterone plus lifestyle therapy improves skeletal muscle glycolysis in older men with obesity and hypogonadism","volume":"16","author":"Viola","year":"2026","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"17","key":"2026090708273334700_ref51","doi-asserted-by":"publisher","first-page":"e0482","DOI":"10.1097\/MD.0000000000010482","article-title":"Effectiveness of testosterone therapy in obese men with low testosterone levels, for losing weight, controlling obesity complications, and preventing cardiovascular events: protocol of a systematic review of randomized controlled trials","volume":"97","author":"Mangolim","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2026090708273334700_ref52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1530\/EJE-21-0473","article-title":"Effectiveness of testosterone replacement in men with obesity: a systematic review and meta-analysis","volume":"186","author":"Mangolim","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2026090708273334700_ref53","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3390\/ph17091233","article-title":"Clomiphene citrate treatment as an alternative therapeutic approach for male hypogonadism: mechanisms and clinical implications","volume":"17","author":"Wu","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026090708273334700_ref54","doi-asserted-by":"publisher","first-page":"1729897","DOI":"10.3389\/fcell.2026.1729897","article-title":"From arthritis to erectile dysfunction: potential pathophysiological mechanisms and multidisciplinary integrated management. Front cell","volume":"14","author":"Wang","year":"2026","journal-title":"Dev Biol"},{"key":"2026090708273334700_ref55","doi-asserted-by":"publisher","first-page":"103464","DOI":"10.1016\/j.eclinm.2025.103464","article-title":"Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis","volume":"88","author":"Chu","year":"2025","journal-title":"EClinicalMedicine."},{"key":"2026090708273334700_ref56","doi-asserted-by":"publisher","first-page":"1720794","DOI":"10.3389\/fcdhc.2025.1720794","article-title":"GLP-1 agonists and exercise: the future of lifestyle prioritization","volume":"6","author":"Codella","year":"2025","journal-title":"Front Clin Diabetes Healthc"},{"issue":"6","key":"2026090708273334700_ref57","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1210\/clinem\/dgab089","article-title":"Erythrocytosis in a large cohort of trans men using testosterone: a long-term follow-up study on prevalence, determinants, and exposure years","volume":"106","author":"Madsen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026090708273334700_ref58","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1097\/JU.0000000000002437","article-title":"Secondary Polycythemia in men receiving testosterone therapy increases risk of major adverse cardiovascular events and venous thromboembolism in the first year of therapy","volume":"207","author":"Ory","year":"2022","journal-title":"J Urol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/9\/qdag272\/70981156\/qdag272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/23\/9\/qdag272\/70981156\/qdag272.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:27:39Z","timestamp":1788784059000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/doi\/10.1093\/jsxmed\/qdag272\/8787137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdag272","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,5]]},"article-number":"qdag272"}}